Washington, D.C. (July 10, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) president and chief executive officer John J. Castellani issued the following statement on passage of the 21st Century Cures Act (H.R. 6) by the U.S. House of Representatives:
"PhRMA applauds the House of Representatives for the overwhelming passage of the 21st Century Cures Act and looks forward to continuing our work with the Senate to ensure biomedical advances continue and are available to the patients who need them to live longer, healthier lives.
We commend Chairman Fred Upton (R-MI), Ranking Member Frank Pallone (D-NJ), Health Subcommittee Chairman Joe Pitts (R-PA), Health Subcommittee Ranking Member Gene Green (D-TX), Congresswoman Diana DeGette (D-CO), and the full Energy and Commerce Committee for their tireless commitment over the past year and a half to engage stakeholders and advance the 21st Century Cures Act with the shared goal of accelerating the discovery, development and delivery of new treatments for patients."
PhRMA’s letter of support for H.R. 6 is available at http://www.phrma.org/21st-century-cures-letter-of-support.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $51.2 billion in 2014 alone.